INTRODUCTION
Most cases of Alzheimer's disease (AD) exhibit sporadic onset during the seventh decade of life or later, whereas the fewer mutation-linked, familial cases typically manifest during the fifth decade. These temporal features, common to numerous neurodegenerative diseases, define aging as the major risk factor for the development of these maladies (Amaducci and Tesco, 1994) . The insulin/insulin-like growth factor (IGF) signaling (IIS) pathway regulates stress resistance, aging and is a life span determinant. IIS reduction results in stress-resistant, long-lived worms (Kenyon et al., 1993) , flies (Tatar et al., 2001) , and mice (Bluher et al., 2003; Holzenberger et al., 2003) and correlates with increased longevity of humans (Flachsbart et al., 2009; Suh et al., 2008; Willcox et al., 2008) . Delayed aging, by IIS reduction, protects worms from proteotoxicity associated with the aggregation of the Huntington's disease-associated polyQ peptide (Morley et al., 2002) and the AD-linked human Ab peptide (Cohen et al., 2006) . However, little is known about whether this protection from proteotoxicity is conserved from worms to mammals, and what protective mechanisms may be operating.
Ab originates from the endoproteolysis of the amyloid precursor protein (APP) (Glenner and Wong, 1984; Selkoe, 2004) . The serine protease BACE (beta amyloid cleaving enzyme) cleaves APP (Farzan et al., 2000) , followed by an intramembrane cleavage of the resulting fragment by presenilin1 (PS1), an active component of the g-secretase proteolytic complex (Wolfe et al., 1999) . These events release the Ab family of aggregation-prone peptides, including Ab 1-40 and the highly amyloidogenic Ab . Although compelling data indicate that Ab aggregation triggers AD, the mechanism leading to the development of the disease is unclear (Selkoe, 2004) . Recent studies suggest that it is not fibrils, but small Ab oligomers lead to toxicity in AD model organisms (Cohen et al., 2006; Lesne et al., 2006) and to AD in humans (Haass and Selkoe, 2007; Shankar et al., 2008) .
In the C. elegans Ab model (Ab worms [Link, 1995] ), the protection from human Ab 1-42 proteotoxicity conferred by IIS reduction is dependent upon two transcription factors, heat shock factor 1 (HSF-1), which regulates Ab disaggregation, and DAF-16 (ortholog to FOXO in mammals), which facilitates the formation of larger, less toxic Ab aggregates. Accordingly, Ab worms protected from Ab toxicity by reduced IIS accumulate more large Ab aggregates and have fewer oligomers than did their unprotected counterparts with normal IIS (Cohen et al., 2006) .
Although reduced IGF signaling extends the life span of mice (Holzenberger et al., 2003) , IGF-1 infusion protects from Ab toxicity (Carro et al., 2002 (Carro et al., , 2006 , raising the query of whether IGF signaling reduction or activation protects from Ab toxicity. To address this question, we created an AD mouse model with reduced IGF signaling by crossing a well-established AD transgenic mouse model (Jankowsky et al., 2001 ) with long-lived mice harboring only one Igf1r gene copy (Igf1r +/À mice) (Holzenberger et al., 2003) .
RESULTS

Creation of Mice with AD Transgenes in the Context of Reduced IGF-1R Signaling
Igf1r is the mammalian ortholog of the sole worm insulin/IGF receptor daf-2 (Kimura et al., 1997) . Igf1r +/À mice exhibit reduced IGF-1 signaling, are long-lived, oxidative stress resistant, and have reduced body size (Holzenberger et al., 2003) . The AD mouse model expresses two AD-linked mutated transgenes, APP swe (a humanized mouse APP that contains the human Ab peptide sequence) and human presenilin-1 DE9, both driven by the mouse prion protein promoter (hereafter referred to as AD mice) (Jankowsky et al., 2001) . The expression of these transgenes results in the production of human Ab amyloid, plaque formation in the brain, and slow, progressive AD-like symptoms (Jankowsky et al., 2004) . The AD-like mice also exhibit age-onset behavioral impairments, analogous to other AD murine models (Reiserer et al., 2007) . The AD model is less aggressive than other AD models, exhibiting appearance of Ab plaques in the brain at 6-7 months of age (Jankowsky et al., 2004) . The slow onset of AD-like symptoms allows for the perturbation of IIS to examine its role in the age onset requirements of the AD-like syndrome.
To equalize the genetic background of our mice, we first backcrossed both the AD and Igf1r +/À mouse strains with wild-type 129 females for three generations, followed by four intercrosses between the AD and Igf1r +/À mice. Crossing Igf1r +/À with the AD mice generated offspring of four genotypes ( Figure 1A ): The original parental genotypes, (1) heterozygous Igf1r +/À (Igfr +/À ) and (2) AD mice, which served as internal controls (AD). (3) Congenic siblings that age naturally due to two Igf1r gene copies but carrying neither of the AD transgenes. These animals served as negative internal controls for asymptomatic AD-like disease and natural IGF-1 signaling (WT). Finally, (4) mice harboring both AD transgenes and only one Igf1r gene copy served as the experimental group of focus (AD;Igf1r +/À ). Quantitative polymerase chain reaction (PCR) analysis revealed that the expression levels of the APP swe transgene were nearly identical in brains of AD and AD;Igf1r +/À mice (Figures S1A-S1E available online), indicating that IGF signaling reduction does not effect the expression of the prion protein promoter-driven transgenes. The levels of monomeric Ab and of the C-terminal APP fragment (APP CTF) were also very similar in AD and AD;Igf1r +/À mice (Figures S1F and S1G). Similarly, reduced IGF signaling did not affect the endogenous a and b secretases (ADAM17 and BACE, respectively) in mouse brains of all genotypes ( Figure S1H ). Together these results indicate that IGF signaling reduction affected neither the transgene expression nor the levels of the endogenous APP processing enzymes or their activity. As expected, both Igf1r +/À and AD;Igf1r +/À mice were smaller compared with their littermates carrying two Igf1r copies, indicating reduced IGF-1R signaling ( Figure S2A ) (Holzenberger et al., 2003) .
Reduced IGF-1R Signaling Reduces the Behavioral Deficits of AD Mice Age-onset memory deficiency and impairment of orientation and locomotion are associated with Ab production in numerous AD murine models (Jensen et al., 2005; King and Arendash, 2002; Westerman et al., 2002) . We evaluated whether reduced IGF-1 signaling protects mice from Ab-associated behavioral impairments using several behavioral assays. As an initial analysis, we used eight animals per genotype and followed their performance in the Morris water maze test at 3, 6, 9, and 12 months of age, and found the greatest differences among AD, AD;Igf1r +/À animals and their littermate controls at the 9 and 12 month time points (Figures S2B and S2C) . At 16 months we observed mortality in the AD group that was not present in the AD;Igf1R +/À mice (data not shown). Thus, we refined our behavioral analysis to the 11-15 month of age using a larger cohort of animals.
We measured the learning ability of mice using a Morris water maze with a cued (visible) platform for four consecutive days. As previously reported for other AD model mice (Blanchard et al., 2008; Westerman et al., 2002) , the AD mice did not exhibit a learning deficiency compared to their age-matched WT, Igf1r +/À , and AD;Igf1r +/À counterparts ( Figure 1B , p > 0.05). In order to test orientation aptitude, we removed the cue from the platform and recorded the latency time required for mice to locate the submerged platform for four consecutive days. At days 2, 3, and 4 of the experiment, AD mice required a significantly (p < 0.05) longer time to find the hidden platform compared to their WT, Igf1r +/À , and AD;Igf1r +/À counterparts ( Figure 1C ). This indicates that, like other mouse AD models (Jensen et al., 2005; King and Arendash, 2002; Westerman et al., 2002) , orientation capabilities of AD animals are impaired (swim velocities were nearly identical for all genotypes; Figure S2D ). Lastly, we tested memory skills by removing the platform from the water maze and recording the number of the crosses of the previous platform location (probe trial). AD mice crossed the platform's previous location significantly (p < 0.05) fewer times than their WT, Igf1r +/À , and most importantly AD;Igf1r +/À counterparts, indicating impaired memory. The observation that AD;Igf1r +/À animals crossed the previous platform location at similar frequencies compared to WT and Igf1r +/À animals suggests partial memory restoration ( Figure 1D ).
Next, we tested the effect of reduced IGF-1 signaling on the motor skills of AD model mice using a Rota-Rod assay. Much like the orientation and memory tests, AD mice performed significantly less well than their age-matched WT, Igf1r +/À , and AD;Igf1r +/À counterparts in this assay ( Figure 1E , p < 0.05).
Collectively, the behavioral data revealed that AD mice have impaired orientation and memory performance as well as locomotion impairment that can be delayed by reduced IGF-1 signaling.
Reduced IGF-1R Signaling Reduces Inflammation and Neuronal Loss in AD Mice
We asked whether the appearance of biological markers associated with AD-like disease in mice was also delayed by reduced , and wild-type, respectively). AD mice performed worst among the four genotypes whereas AD;Igfr +/À mice where partially rescued because they performed significantly better than AD animals (p < 0.05, Tuckey LSD). No statistical difference appeared between AD;Igfr +/À animals and the two control genotypes. In all behavioral tests, 11-to 15-month-old mice were tested and age-match controlled. Error bars represent mean and standard error of the mean (± SEM).
IGF signaling. First we tested whether reactive astrocytosis, indicative of neuroinflammation, associated with AD in humans (Mancardi et al., 1983) , and with Ab aggregation in brains of AD model mice (Wirths et al., 2008) , was reduced in AD;Igf1r
animals. Utilizing glial fibrillary acidic protein (GFAP) antibodies, which recognize activated astrocytes (Mancardi et al., 1983) , we found notably less activated astrocytes in the brains of AD;Igf1r +/À mice compared with age-matched AD mice (Figure 2) . This reduction was apparent both in the cortex and hippocampus ( Figure 2I ), indicating that neuroinflammation is reduced in AD;Igf1r +/À mice compared with age-matched AD mice. Interestingly, whereas the GFAP signal observed in cortices of AD mice was largely diffuse, cortical GFAP staining of AD;Igf1r +/À mice appeared to be focal (compare Figures 2C and 2D ), suggesting that neuroinflammation within AD;Igf1r +/À brains is confined to smaller areas than in the brains of AD animals. Neuronal loss is another hallmark of AD in humans (Scheff et al., 1990) and AD model mice (Masliah and Rockenstein, 2000) . We used direct stereological visualization and NeuN immunoreactivity, a marker of neuronal density that declines in AD mice, and found higher NeuN immunoreactivity in the cortices of 12-to 13-month-old AD;Igf1r +/À mice compared to their age-matched AD counterparts ( Figure 3 ). This indicates that reduced IGF signaling protects from neuronal loss. Similar neuronal losses were observed in young (4-5 months of age) and in old (16-17 months) AD but not in AD;Igf1r +/À mice when compared to age-matched control genotypes ( Figure S3 ). Reduced synaptic density is an additional hallmark and probably causative of AD (Hamos et al., 1989) . Thus, we used the synaptic marker synaptophysin to compare synaptic densities in frontal and hippocampal brain regions of 12-to 13-monthold mice of all genotypes (Hamos et al., 1989) and found significantly lower synaptic densities in both brain regions (Figures 3J and 3K, respectively) of AD animals compared with their AD;Igf1r +/À counterparts. These observations confirm that IGF signaling reduction protects mice form Ab-associated neuronal loss.
Reduced IGF Signaling Promotes the Formation of Densely Packed Aggregates
To explore the mechanism underlying the protection toward behavioral deficiencies conferred by reduced IGF signaling, as well as the protection from inflammation and neuronal loss in mice ectopically expressing mutated AD-linked transgenes, we investigated the nature of Ab assemblies in brains of AD and AD;Igf1r +/À mice. Immunohistochemistry (IHC) and Ab antibodies (clone 6E10) were used to visualize Ab plaques in brain sections of AD and AD;Igf1r +/À mice ( Figure S4 ). Consistent with previous results (Jankowsky et al., 2004) , Ab plaques could not be detected in brains of young mice (4-5 months old). A few plaques were observed in the brains of 8-to 9-month-old animals, whereas the number of plaques increased in the brains of 12-to 13-month-old AD and AD;Igf1r +/À mice. No background staining was observed in brains of WT or Igf1r +/À mice at any age examined ( Figure S4 ). Thus, reduced IGF signaling has no apparent effect on the onset of plaque formation. Next we used the fluorescent dye Thioflavin-S to visualize amyloid within AD and of AD;Igf1r +/À brains and found nearly identical amyloid load in cortex and hippocampus regions of both genotypes ( Figure 4A , panel IX). (Colocalization of Thioflavin-S labeling with the signal of specific Ab antibody [clone 82E1] confirmed the plaque specificity of Thioflavin-S; Figure S5A ). Therefore, the kinetics of Ab plaque appearance as well as the amyloid load did not appear to differ between AD and AD;Igf1r we used the highly specific Ab antibody (clone 82E1 that recognizes processed Ab) and measured the Ab immunoreactive optical density (signal per area) in the different brains. Significantly higher Ab immunoreactive optical densities were detected in brains of AD;Igf1r +/À mice than in AD brains ( Figure 4B , panel IX), suggesting higher compaction of the Ab amyloid plaques in AD;Igf1r +/À animals. We also compared the protease sensitivity of plaques of AD and AD;Igf1r Figure S6B ).
To quantify and compare the density of the amyloid plaques of AD and AD;Igf1r +/À mouse brains, we developed an electron microscopy (EM) image-processing algorithm that identifies the gold particles conjugated to the Ab antibodies ( Figures  S6C-S6F) , sets a region of interest (ROI) around each particle, and determines the median signal density within the ROI after excluding the gold particle ( Figures S6G-S6I ). ROIs that contain dense structures will have a lower score value due to less bright pixels and more dark pixels (i.e., lower gray-scale value). Cortices of six 12-to 13-month-old AD mice and five AD; Igf1r +/À mice were visualized by EM and 135 images (34,087
ROIs) of AD and 101 images (26,066 ROIs) of AD;Igf1r +/À were automatically segmented and analyzed in an unbiased manner. The distributions of ROI median signal intensities indicate that plaques of AD;Igf1r +/À mice were significantly (p < 0.038) denser than those of age-matched AD counterparts ( Figure 5B ). The possibility that antibody accessibility to plaques of AD and 
Igf1r
+/À (B and F) mice were comparable, while remarkable neuronal loss was observed in brains of age-matched AD animals (C and G).
(I) Image analysis of the NeuN signals indicated that neural density in both cortices and hippocampuses of AD animals was significantly lower compared with their age-matched WT counterparts (cortex: p < 0.001, one-way ANOVA, F = 16.03; hippocampus: p < 0.05, Kruskal-Wallis c 2 = 9.36, df = 3). No significant difference was observed among brains of AD;Igf1r +/À and Igf1r +/À mice (six mice per genotype and three sections per animal were analyzed).
(J and K) Immunohistochemistry using synaptophysin antibody revealed that AD;Igf1r +/À mice exhibit significantly higher synaptic densities than their age-matched AD counterparts in both frontal (J) and hippocampal (K) brain regions (AD n = 7, AD;Igf1r +/À n = 5). Error bars represent mean ± SEM.
AD;Igf1r
+/À brains differs was assessed by a second algorithm designed to measure the distance between each gold particle and its closest neighboring particle. This algorithm is based on the assumption that lower accessibility would result in sparse distribution and longer distances among the gold particles. Automatic processing of all plaque images of AD and AD;Igf1r
showed no difference in distances ( Figure S6J , p > 0.54), indicating similar antibody accessibilities.
The results obtained using light and electron microscopy suggest that reduced IGF signaling mediates the assembly of Ab into more condensed amyloid plaques of lower toxicity. We used an in vitro kinetic aggregation assay (Cohen et al., 2006) to assess the relative total amounts of Ab amyloid in equal volumes of brains of AD and AD;Igf1r +/À mice. When proteinase K-treated and sonicated (fragments fibrils into a uniform size) brain homogenate is added to an Ab 1-40 aggregation reaction, the reduction in the time that it takes the aggregation reaction to reach 50% completion is proportional to the amount of Ab amyloid fibrils in the tissue (Cohen et al., 2006 ) (D.D. and J.K., unpublished data). The amyloid load was assessed in 4-to 5-month-old and of 12-to 13-month-old AD and AD;Igf1r +/À mouse brain homogenates (nine animals per genotype). While no significant difference in aggregate load could be detected among brain homogenates of young animals (4-5 months old, Figure S6K ), brain extracts of 12-to 13-month-old AD;Igf1r +/À mice exhibit a higher aggregate load reflected by a shorter t 50 , (suggesting accelerated aggregation of Ab 1-40 ) relative to agematched AD animals ( Figure 5C ; p = 0.035). These data demonstrate that there is more amyloids in an equal volume of 12-to 13-month-old AD;Igf1r +/À brain relative to AD brain. These results are consistent with the light and electron microscopy data indicating that protected AD;Igf1r +/À animals have more densely packed Ab aggregates than AD animals. (B) Ab plaque signal density was measured using Ab-specific antibody (82E1). The signal per area ratio in brains of AD;Igf1r +/À animals (panels IV and VIII) was significantly higher (panel IX, p < 0.05) compared with brains of age-matched AD animals (panels III and VII), indicating higher plaque compaction in brains of AD;Igf1r +/À mice (six mice per genotype and three sections per animal were analyzed; DG, dentate gyrus; NC, neocortex). Error bars represent mean ± SEM.
Ab. Thus, we tested whether more soluble Ab is present in AD compared to AD;Igf1r +/À brain homogenates. We spun brain homogenates of seven AD and nine AD;Igf1r +/À 12-to 13-monthold mice to sediment highly aggregated Ab (10,000 g for 10 min, 4 C) and quantified the lower molecular weight (MW) Ab 1-40 and Ab 1-42 levels in the soluble fractions using enzyme-linked (E) Native SEC indicated that Ab dimers were mainly associated with large structures in brains of 16-to 17-month-old AD;Igf1r +/À mice (panel iii) while more soluble in brains of age-matched AD animals (panel ii, arrowhead) (panels represent 6 AD and 6 AD;Igf1r +/À animals that were analyzed). Loading of total samples onto the gel and subsequent WB analysis using 6E10, confirmed equal protein loading onto the column (panel i).
Error bars represent mean ± SEM (A, B, and D).
Next, we tested whether SDS-soluble Ab oligomeric content and total quantities were affected by reduced IGF-1 signaling. Four AD and 4 AD;Igf1r +/À mouse brains of 12-to 13-monthold mice were subjected to an Ab oligomer preparation protocol (Bar-On et al., 2006) followed by SDS-PAGE and western blot (WB) analysis. Surprisingly, the SDS-soluble Ab oligomer content, and total quantities and amounts of APP were indistinguishable in the total brain homogenates ( Figures 6C and 6D ) of AD and of AD;Igf1r +/À mice (no oligomers could be detected in cytosolic fractions; Figure S7B Figure 6E , panel i) were loaded onto a size-exclusion column, and 20 fractions were collected, lyophilized, resuspended, and loaded onto SDS gels. Ab assemblies were visualized using WB and Ab antibody (6E10). Notably, higher MW assemblies were observed in the AD;Igf1r +/À (see red reference line) reflecting that they were larger to begin with and/or that they were more SDS resistant ( Figure 6E Ab fibrils are denser, more SDS resistant and more efficiently prevent the release of potentially toxic oligomeric species. Since toxicity has been previously associated with the capacity of high-MW assemblies to fragment (Shankar et al., 2008) , prior correlations between the appearance of small SDS-stabilized Ab species and neurotoxicity may reflect this. The data obtained from the microscopic analyses, ELISA and in vitro assays suggest that the conversion of oligomers into denser, higher MW, more SDS-resistant aggregates is part of the process that protects against proteotoxicity in the AD;Igf1r +/À animals.
DISCUSSION
By comparing behavioral and pathological aspects of Alzheimer's-like disease in the AD and AD;Igf1r +/À mice, we found that reduced IGF-1 signaling notably protects mice from proteotoxicity associated with the expression of the AD-linked human peptide, Ab. Light and electron microscopy, as well as in vitro kinetic aggregation, ELISA, and SEC assays, all indicate that reduced IGF-1 signaling induces the assembly of Ab into densely packed, larger fibrillar structures late in life. The observation that the protected AD;Igf1r +/À mice form SDS stable Ab assemblies, making it more difficult to generate presumably toxic Ab dimers (Shankar et al., 2008) , suggests that an active mechanism converts oligomers into densely packed aggregates of lower toxicity that protect the AD;Igf1r +/À mice from proteotoxicity. This hypothesis is consistent with results obtained in the Ab worm model, where reduced insulin/IGF signaling protected worms from Ab-associated toxicity while increasing the formation of high-MW Ab aggregates (Cohen et al., 2006) . How can increased Ab aggregation protect against proteotoxicity? Highly aggregated Ab is thought to bear lower toxicity in comparison to oligomers (Haass and Selkoe, 2007) . Accordingly, enhanced fibrillization can reduce Ab toxicity in an AD-murine model (Cheng et al., 2007) . Furthermore, results from longterm potentiation assays show that highly aggregated Ab bears lower toxicity than small oligomers (Shankar et al., 2008) . Intriguingly, the release of small oligomers, most notably dimers, from large Ab assemblies (fibrils) by chemical extraction increases toxicity. In support of the hypothesis that accelerated aggregation can be protective is provided by the discoveries that the cellular chaperones HSP104 (Shorter and Lindquist, 2004) and TRiC (Behrends et al., 2006) , both known to disrupt toxic protein aggregates can also mediate protection by accelerating aggregation when the concentration of the aggregating protein exceeded a threshold level. These studies raise the prospect that the creation of densely packed, large Ab assemblies protects AD;Igf1r +/À mice from proteotoxicity by trapping and storing highly toxic small aggregate structures. If active aggregation protects from Ab toxicity, such protective mechanism might be expected to be negatively regulated by the IGF signaling pathway. In the worm, this activity is mediated, at least in part, by the FOXO transcription factor DAF-16 (Cohen et al., 2006) , which is negatively regulated by the IIS receptor DAF-2. The FOXO gene family is highly conserved in mammals, is expressed in neurons, and is required for neuronal survival under stress (Lehtinen et al., 2006) , suggesting that FOXO transcription factors are also mediators of the reduced IGF signaling protective effect in mammals. It is likely that reduced IGF signaling ameliorates Ab proteotoxicity by mechanisms in addition to Ab dense fibril formation. The observation that Igf1r +/À mice exhibit increased resistance to oxidative stress (Holzenberger et al., 2003) raises the possibility that reduced IGF-1 signaling enhances the neuronal counter proteotoxic capabilities by enhancing the levels of enzymes that protect against oxidative stress proposed to be involved in AD-associated brain damage (Fukui et al., 2007) . This is supported by the observation that the production of reactive oxygen species is reduced in brains of Igf1r +/À mice compared with their WT counterparts following MPTP treatment known to induce a Parkinson's disease-like phenotype (Nadjar et al., 2008) . Moreover, overexpression of mitochondrial-targeted catalase promotes longevity of mice (Schriner et al., 2005 ). An alternative model suggests that increased neuronal resilience associated with reduced IGF signaling is promoted by enhanced DNA repair capabilities. It is reasonable to speculate that the histone deacetylase SIRT1, an aging regulator (Ghosh, 2008) that plays roles in the maintenance of genomic stability (Oberdoerffer et al., 2008) and regulates HSF1 (Westerheide et al., 2009) , may also be a mediator of the reduced IGF signaling protective effect in the AD;Igf1r +/À mice. The complexity and variety of effects mediated by FOXO (Partridge and Bruning, 2008) propose that reduced IGF signaling orchestrates an array of counter proteotoxic activities including Ab hyperaggregation, counter oxidation activities, and presumably other yet to be defined mechanisms (Figure 7 ). Further research is required to elucidate whether mammalian FOXO family members play roles in the protective mechanism toward AD. The Ab hyperaggregation observed in protected AD;Igf1r +/À mouse brains suggested that Ab plaques would be visible in the cortex of these animals at younger ages compared to their unprotected AD counterparts, however, this was not evident in our analysis. This is likely due to other mechanisms of protein homeostasis being effective early in life, such as the disaggregase and degradation activity regulated by HSF-1, as observed in the worm (Cohen et al., 2006) . In this view, the protective disaggregation/degradation and hyperaggregation mechanisms may be temporally distinct. Active hyperaggregation may only be invoked once the primary disaggregation machinery can no longer effectively clear toxic Ab species as a consequence of aging or an extrinsic stress. It will be interesting to evaluate whether one or more of the four HSF genes in the mouse are involved in protecting the brain from Ab toxicity throughout life, and whether FOXO activity becomes prominent later in life.
There is an apparent contradiction between the data presented herein and earlier reports that IGF infusion protects rats (Carro et al., 2002) and mice (Carro et al., 2006) from Ab proteotoxicity and that IGF-1R blockade induced neurological disease in rats (Carro et al., 2006) . The presence of feedback-signaling events that respond to the sudden increase in IGF concentration by tuning down the responsiveness of the IGF signaling cascade over time could explain why IGF infusion is protective against AD-like pathology (Cohen and Dillin, 2008) . This explanation is supported by many observations. For example, long-lived female human centenarians have high serum IGF-1 levels, but low IGF-1R activity, leading to reduced IGF signaling (Suh et al., 2008) . Therefore, high IGF-1 levels do not necessarily correlate with increased downstream activity over a prolonged time. Additionally, AD patients have lower than normal serum insulin concentrations, but higher than normal CSF insulin levels (Craft et al., 1998) . These studies raise the prospect that insulin and IGF signaling are regulated in a tissue-specific manner, and suggest that peripheral IGF infusion may lead to reduced IGF signaling in the brain (Cohen and Dillin, 2008) .
The data presented here demonstrate that reduced IGF-1R signaling results in a profound reduction in the toxicity associated with Ab expression in the brains of mice. The formation of larger and denser Ab aggregates that appear to be more SDS resistant in the AD;Igf1r +/À mice suggests that this is one core protective activity regulated at least in part by IGF-1R signaling, much like the disaggregase activity reported previously (Cohen et al., 2006) . The indication that reduced IIS is protective in nematodes and mammals stresses that manipulation of the highly conserved IGF signaling pathway, and its downstream components, is promising for the development of novel neurodegeneration and proteotoxicity therapies.
EXPERIMENTAL PROCEDURES
Mouse Strains and Genotyping AD-model male mouse expressing a mutant chimeric mouse/human APP swe and a mutant human presenilin 1 (Delta E9) both driven by the prion protein promoter was purchased from Jackson laboratory (strain B6C3-Tg [APP swe PSEN1 dE9] 85Dbo/J, stock number 004462).
Long-Lived, Compromised IIS Mice
Males harboring only one Igf1r copy (S129 background [Holzenberger et al., 2003] ) were obtained from Dr. Jeffery Friedman (TSRI, La Jolla, CA). Males of both strains were crossed for three generations with ''wild-type'' 129 females (Jackson laboratories, strain 129Xi/SvJ, stock number 000691), to set up two separate colonies. Mice of each colony were backcrossed for additional two generations. Next, Igf1r
+/À males were crossed with AD females for three generations to generate the experimental mice.
DNA was purified from biopsies of mouse tails and subjected to PCR. APP swe and PS1DE9 were amplified as directed by the Jackson Laboratories. Igf1r was amplified using the following primers: forward: GTATAGTCCTA GAGGCCC; reverse: GTTCTGGCAGAAAACATGG. The digestion of APP creates Ab monomers that spontaneously aggregate to form toxic oligomers in vivo. At least two biological mechanisms can detoxify Ab oligomers: (1) conversion of toxic oligomers into monomers (disaggregation), and (2) conversion of toxic oligomers into less toxic, larger structures (active aggregation). Within scenario 1, IGF-1 signaling normally functions to reduce protein disaggregases. Therefore, reduction of IGF-1 signaling would result in less oligomers and more monomeric forms of Ab due to the activation of protein disaggregases. Our results are inconsistent with this scenario because we find less oligomers, but equal amounts of monomeric Ab. Alternatively, in scenario 2, IGF-1 signaling could normally function to reduce protective protein aggregases that convert toxic species into larger, less toxic forms. Thus, reduced IGF-1 signaling elevates aggregase activity that in turn reduces the load of toxic oligomers and increases the compaction of less toxic fibrils. In support of scenario 2, we observed less soluble oligomers and highly compact amyloid plaques in AD;Igf1r +/À animals. Alternatively, (3) IGF-1 signaling could promote proteotoxicity and neuroinflammation in response to toxic Ab assemblies. Our results are also consistent with this proposed mechanism as we observed much less neuroinflammation in the brains of protected AD;Igf1r
animals. Yet this lower inflammation rate could be directly related to the reduction of Ab oligomers in these animals by increased aggregases. In scenario 4, reduction of toxic secondary factors, such as reactive oxygen species (ROS), might synergize with the production of toxic Ab assemblies to promote neuronal loss. Consistent with this mechanism, Igf1r +/À mice are much more resistant to oxidative damage than wild-type mice. Taken together, IGF-1 signaling could impinge at multiple steps on the path to neuronal loss and neurodegeneration in response to Ab production and none of the interventions are mutually exclusive. Our data are most consistent with a model in which reduced IGF-1 signaling reduces the load of toxic Ab structures, presumably dimers, which results in higher compaction of plaques, reduced neuroinflammation, and reduced neuronal loss.
Western Blot Analysis
Brains were dissected, homogenized, and divided by ultracentrifugation (100,000 g, 1 hr, 4 C) into cytosolic and membrane (particulate) fractions.
For WB analysis, 15 mg per lane of cytosolic and particulate fractions, assayed by the Lowry method, were loaded into 10% SDS-PAGE gels and blotted onto nitrocellulose paper. Blots were incubated O/N with antibodies against APP/ Ab (6E10), Ab (82E1), and C terminus APP (CT-15, courtesy of Dr. Ed Koo). Next, membranes were incubated with secondary antibodies tagged with horseradish peroxidase (1:5000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), visualized by enhanced chemiluminescence and analyzed with a Versadoc XL imaging apparatus (Bio-Rad, Hercules, CA). Actin served as a loading control.
Rota Rod
Locomotion was tested using Rota Rod system (EconoMex, Columbus Instruments, Columbus, OH). Four mice were place at a time on the rotating beam set to accelerate at 0.2 rpm/s. Time from start until each mouse fell off was recorded. Each mouse was trained 1 day for five times prior to the experiment. Each mouse was tested five times a day, for 4 sequential days (total of 20 measurements/mouse/ age). At least 12 animals (males and females) per genotype were used in each time point (Supplemental Statistical Data).
Morris Water Maze
The Morris water maze was conducted as described previously (Jensen et al., 2005) . Briefly, 11-to 15-month-old mice of the four genotypes were placed one animal per cage and numbered randomly to avoid genotype identification during the experiment. A plastic tank 120 cm in diameter was filled with room temperature (RT) water (23 C), which was made opaque with white nontoxic paint. A transparent platform (8 cm 3 12 cm) was located in the center of one of the four virtually divided quadrants and was submerged 0.5 cm below the water surface to be invisible. Distal cues were provided in all experiments as spatial references. Mice were let swim until platform was found or for a maximum of 60 s. Mice were allowed to rest on the platform for 15 s between trials. In all experimental settings we utilized a video tracking system (Ethovision; Noldus Information Technology, Leesburg, VA) to record and analyze the swimming path, swim velocity, time taken to reach the platform (latency), and time spent in each quadrant. The experiments were performed at the following order: cued platform (4 sequential days), hidden platform (4 sequential days), probe trial (1 day). The number of animals used was 13 (WT), 12 (Igf1r 
Cued Platform
For the cued version of water maze testing, the platform was located 0.5 cm below the opaque water level but made clearly visible to the mouse by locating a 15 cm high stick carrying a dotted flag (3 cm 3 4 cm) on the platform. The platform location was fixed throughout the experiment. The mice were released from four different locations around the water tank.
Hidden Platform
The platform was located at the same location used for the cued platform experiment, 0.5 cm below the opaque water level but without the dotted flag, to be invisible. The mice were released from four different locations around the tank. Time of latency, swim velocity, path length, and time spent at each quadrant were recorded.
Probe Trial
The platform was removed and the mice were allowed to swim for 40 s. The time spent in each quadrant and in the previous platform location, number of crossing the area where the platform was previously located, swim velocity, and path length were recorded.
Size-Exclusion Chromatography A Superdex 75 10/300 GL column (Cat # 17-5174-01 GE Healthcare, Uppsala Sweden) attached to an AKTA FPLC system was used to separate Ab oligomers from mouse brains. Column was calibrated using low MW calibration kit (GE Healthcare cat # 28-4038-41). Then 250 ml 10% (w/v) mouse brain homogenate (in PBS) was injected into the column and eluted with 50 mM ammonium acetate (pH 8.5) at flow rate of 0.5 ml/min. Twenty 1 ml fractions were collected, lyophilized, resuspended in 120 ml PBS and 40 ml LDS sample buffer, boiled for 10 min, and separated on 4%-12% Bis-Tris gels as described above.
Morphological and Postembedding Immunoelectron Microscopy WT, Igf1r
, AD, and AD;Igf1r +/À mice were sacrificed at the indicated ages.
A piece of cortex from each mouse brain was fixed for 24 hr in cold 2% paraformaldehyde and 0.25% glutaraldehyde in PBS followed by washing in PBS and postfixed in 1% osmium tetroxide in PBS. The samples were washed in PBS and dehydrated in graded ethanol solutions followed by propylene oxide and embedded in Epon/Araldite mixture (Cat # 13940, Electron Microscopy Sciences, Hatfield, PA). The polymerized resin was sectioned (70 nm) using a diamond knife (Diatome, Hatfield, PA) and mounted on uncoated 400 mesh nickel grids (Cat# G400-Ni, Electron Microscopy Sciences) for immunolabeling. Antigen retrieval was performed using sodium m-periodate-saturated aqueous solution for 10 min followed by TBS (50 mmol/l Tris-HCl, 150 mmol/l NaCl [pH 7.4]) wash. Sections were background blocked in 3% bovine serum albumin (BSA) in TBS for 30 min followed by an overnight incubation in primary Ab 1-42 affinity purified polyclonal rabbit antibody, which recognizes the C terminus of the peptide (Cat # AB5078P Chemicon-Millipore, Temecula, CA) 1:50 in 1% BSA in TBS at RT. Sections were washed 3 times in TBS and blocked in 3% BSA in TBS for 30 min followed by 2 hr incubation in protein A conjugated to 10nm gold particles (Cat # EM PAG10 BB International, Cardiff, UK) diluted 1:100 in 1% BSA in TBS at RT, rinsed three times in TBS, three times in H 2 O, and air dried. Higher contrast was achieved with 2% uranyl acetate in 50% ethanol for 10 min and in Reynold's lead citrate solution (120 mmol/l sodium citrate, 25 mmol/l lead citrate [pH 12]) for 1.5 min. The specimens were studied in a Jeol 100CX electron microscope (Jeol, Akishima, Tokyo, Japan) at 100 kV. Electron micrographs were taken with a Mega View III CCD camera (Soft Imaging System GmbH, Muenster, Germany) and Analysis Pro v 3.2 digital micrograph software (Soft Imaging System GmbH). For detailed description and software for EM particle analysis, please see Supplemental Data and http://sites.dillinlab.googlepages.com.
In Vitro Kinetic Ab Aggregation Assay Ab 1-40 peptide (10 mM in phosphate buffer: 300 mM NaCl, 50 mM Na-phosphate [pH 7.4]) was labeled with ThT (20 mM). Mouse brain homogenate was sonicated for 40 min (FS60, Fisher Scientific, Pittsburg, PA), treated with proteinase K (2h, 0.2 mg/ml), and supplemented with complete EDTA-free protease inhibitor cocktail (cat#1836170 Roche, Basel Switzerland). Three aliquots (100 ml each, total protein concentration of 10 mg/ml) were transferred into a 96-well microplate (Costar black, clear bottom) for each reaction. The plate was loaded into a Gemini SpectraMax EM fluorescence plate reader (Molecular Devices, Sunnyvale, CA), incubated at 37 C, and fluorescence (excitation at 440 nm, emission at 485 nm) was measured from the bottom at 10 min intervals, with 5 s of shaking before each reading. Half-maximal fluorescence time points (t 50 ) were defined as the time point at which ThT fluorescence reached the middle between pre-and postaggregation baselines. 
